Industry watchers knew Medicare would be shelling out a whole lot more on hepatitis C treatments last year, thanks to new-and-improved drugs. But just how much more did it cough up?
Not long after Gilead Sciences' high-priced hep C super drugs Sovaldi, and then combo drug Harvoni, hit the market, the California drugmaker struck deals with 11 generic drugmakers to make cut-rate versions available, and affordable, in 91 developing countries. But Gilead is not as generous as it might seem, Doctors Without Borders claims.
After agreeing to shell out a pretty penny for Imbruvica-maker Pharmacyclics earlier this month, AbbVie chief Richard Gonzalez assured investors that the drug had plenty of market growth ahead--and that much of that growth would come from moving into earlier lines of treatment in its approved indications, including CLL. Now, new Phase III results suggest the med is on the right track in that department.
Much-anticipated data on AstraZeneca's clot-fighting drug Brilinta, unveiled over the weekend at the American College of Cardiology meeting, showed that Brilinta did stave off serious cardiovascular problems, when used long term alongside aspirin. But the numbers were small enough--and the bleeding risks high enough--to put a damper on new sales hopes.
U.S. prescription drug spending shot up 13.1% last year, according to a new report from Express Scripts. And the vocal price critic says it knows just who's to blame.
It's just Friday, but the Monday morning quarterbacking on AbbVie's Pharmacyclics buy is in full swing. Did AbbVie overpay at $21 billion? Should it have let Johnson & Johnson take the prize instead? Does the rich deal for Pharmacyclics spell trouble for pharmas looking to make biotech buys? And really, did AbbVie overpay?
It's more bad news for Eli Lilly's Alimta in Europe. After losing a patent fight last year with Actavis in England, the Indianapolis drugmaker has now lost another in Germany, paving the way for knockoff versions of its top drug there.
Bristol-Myers Squibb and Pfizer got a positive recommendation from the U.K.'s cost gatekeeper for its new-age clot-fighter Eliquis, giving the companies a boost as they chase $3 billion in sales for the drug and compete with rivals Pradaxa and Xarelto.
Ten companies count on one top product to supply a major chunk of their sales, the business news site Quartz calculates. And several of those are either anticipating some serious pain from a near-term patent expiration or already suffering from competition.
Interim results are in from Amgen's head-to-head trial between its blood cancer drug Kyprolis and Takeda's Velcade, and things are looking good for the California biotech. Twice as good as they are for Takeda, in fact, when it comes to progression-free survival.